

<http://www.globenewswire.com/newsroom/news.html?d=203656>

Repros Therapeutics and Adventrx Pharmaceuticals Presenting at the 2010 Sunshine on Wall Street Healthcare Dinner Conference

FORT LAUDERDALE, Fla., Oct. 13, 2010 (GLOBE NEWSWIRE) -- Repros Therapeutics, Inc. (Nasdaq:[RPRX](#)) and Adventrx Pharmaceuticals, Inc. (AMEX:[ANX](#)) will be in Fort Lauderdale, Florida on October 13th, 2010 for Sunshine on Wall Street, hosted by LDV Capital Management, in conjunction with the Stock and Bond Club of South Florida.

Founded in 1965, the Stock and Bond Club of South Florida is the largest association of investment advisors in South Florida. The dinner affair will be from 5:30 p.m. to 8:05 p.m. at DeerCreek Country Club at 2801 Country Club Boulevard, Deerfield Beach, Florida 33442.

DINNER FORMAT:

Cocktail hour: **5:30 p.m. to 6:20 p.m.**

Dinner Begins: **6:30 p.m. to 7:15 p.m.**

Presentation 1: **6:45 p.m. to 7:15 p.m.**

Presentation 2: **7:20 p.m. to 7:50 p.m.**

Lightning Round Closing Summary: **7:50 p.m. to 8:00 p.m.**

PRESENTING COMPANIES:

REPROS THERAPEUTICS, INC., (Nasdaq:[RPRX](#)), focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. The company's primary product candidate includes Androxal that completed Phase IIb proof-of-concept trial in men being treated for low testosterone levels who want to improve or maintain their fertility and/or sperm number and function; and is in the Phase IIa clinical trial for the treatment of hypogonadal men with type 2 diabetes. It also offers phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction. Repros Therapeutics, Inc. was founded in 1987 and is based in The Woodlands, Texas. <http://www.reprosrx.com>.

ADVENTRX PHARMACEUTICALS, INC., (AMEX:[ANX](#)), focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, (aka Exelbine™), an emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, an emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The company was founded in 1995 is headquartered in San Diego, California. <http://www.adventrx.com>

To expedite registration, call LDV Capital Management at: 954-746-3117, www.LdvCapitalManagement.com, or email Jim@LdvCapitalManagement.com.

DISCLAIMER: LDV Capital Management is a Registered Investment Advisory firm licensed with the State of Florida. The information herein is not a solicitation to invest, but simply information compiled from company press releases and company public information. Information is believed to be reliable, but makes no representation to its accuracy or completeness. LDV does not recommend, warrant, or guarantee the success of any action taken in reliance on statements

and professional advice should be sought before making any investment decisions. As in any investment, risks apply, where part of or all investment capital can be lost. Presenting Companies paid a sponsorship fee to present at the Conference. Scheduled times, agendas, and presenters are subject to change. LDV, nor any of its principles or employees do not hold any stock positions in any of the companies mentioned above.

CONTACT: LDV Capital Management
954-746-3117